Stifel Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $21 to $24.
May 30, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Benjamin Burnett maintains a Buy rating on Iovance Biotherapeutics and raises the price target from $21 to $24.
The news of Stifel maintaining a Buy rating on Iovance Biotherapeutics and raising the price target from $21 to $24 is positive for the stock. This indicates that the analyst has confidence in the company's growth potential and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on IOVA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100